Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Pharmacokinetics of Alemtuzumab Used as Conditioning Agent in Reduced Intensity Transplantation for Pediatric Non-Malignant Disorders.

Julie Kanter, MD, Manasa Kanthamneni, Shannon Witty, Yvonne Barnes, Robert Hayashi, Shalini Shenoy

Blood (2008) 112 (11): 3290.

https://doi.org/10.1182/blood.V112.11.3290.3290

Published: 2008

Journal Articles

Unrelated Donor Hematopoietic Cell Transplant (HCT) for Hemophagocytic Lymphohistiocytosis (HLH).

K. Scott Baker, MD, Mary Eapen, MBBS, Thomas Gross, MD, Gregory A. Hale, MD, Robert Hayashi, MD, Naynesh R. Kamani, MD, Neena Kapoor, MD, Alexandra Filipovich, MD

Blood (2006) 108 (11): 174.

https://doi.org/10.1182/blood.V108.11.174.174

Published: 2006

Journal Articles

Impact of Hematopoietic Cell Transplantation with Total Body Irradiation on the Health Status of Childhood Leukemia Survivors: A Report from the Childhood Cancer Survivor Study (CCSS).

K. Scott Baker, MD, Wendy Leisenring, ScD, Robert Hayashi, MD, Amanda Termuhlen, MD, Ann Mertens, PhD, Sarah Donaldson, MD, John Whitton, MS, Marilyn Stovall, PhD, Leslie Robison, PhD, Charles Sklar, MD

Blood (2005) 106 (11): 1109.

https://doi.org/10.1182/blood.V106.11.1109.1109

Published: 2005

Journal Articles

Anti-CD20 Monoclonal Antibody (rituximab) for Refractory PTLD after Pediatric Solid Organ Transplantation: Multicenter Experience from a Registry and from a Prospective Clinical Trial.

Steven Webber, MBChB, William Harmon, MD, Albert Faro, MD, Michael Green, MD, Minnie Sarwal, MD, Robert Hayashi, MD, Charles Canter, MD, Dawn Thomas, RN, Ron Jaffe, MD, Richard Fine, MD

Blood (2004) 104 (11): 746.

https://doi.org/10.1182/blood.V104.11.746.746

Published: 2004

Journal Articles

Reduced Intensity Conditioning Therapy Using Campath -1H Is Successful for Stem Cell Transplantation in Non-Malignant Disorders.

Aarati Rao, MD, Robert Hayashi, MD, William Grossman, MD, PhD, David Wilson, MD, PhD, Lolie Yu, MD, John DiPersio, MD, PhD, Yvonne Barnes, PNP, Shalini Shenoy, MD

Blood (2004) 104 (11): 1823.

https://doi.org/10.1182/blood.V104.11.1823.1823

Published: 2004

NARROW

Pharmacokinetics of Alemtuzumab Used as Conditioning Agent in Reduced Intensity Transplantation for Pediatric Non-Malignant Disorders.

Unrelated Donor Hematopoietic Cell Transplant (HCT) for Hemophagocytic Lymphohistiocytosis (HLH).

Impact of Hematopoietic Cell Transplantation with Total Body Irradiation on the Health Status of Childhood Leukemia Survivors: A Report from the Childhood Cancer Survivor Study (CCSS).

Anti-CD20 Monoclonal Antibody (rituximab) for Refractory PTLD after Pediatric Solid Organ Transplantation: Multicenter Experience from a Registry and from a Prospective Clinical Trial.

Reduced Intensity Conditioning Therapy Using Campath -1H Is Successful for Stem Cell Transplantation in Non-Malignant Disorders.

Email alerts

ASH Publications

American Society of Hematology

Pharmacokinetics of Alemtuzumab Used as Conditioning Agent in Reduced Intensity Transplantation for Pediatric Non-Malignant Disorders.

Unrelated Donor Hematopoietic Cell Transplant (HCT) for Hemophagocytic Lymphohistiocytosis (HLH).

Impact of Hematopoietic Cell Transplantation with Total Body Irradiation on the Health Status of Childhood Leukemia Survivors: A Report from the Childhood Cancer Survivor Study (CCSS).

Anti-CD20 Monoclonal Antibody (rituximab) for Refractory PTLD after Pediatric Solid Organ Transplantation: Multicenter Experience from a Registry and from a Prospective Clinical Trial.

Reduced Intensity Conditioning Therapy Using Campath -1H Is Successful for Stem Cell Transplantation in Non-Malignant Disorders.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only